UBS Group’s Aevi Genomic Medicine Inc GNMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-198,732
| Closed | -$29K | – | 8839 |
|
|
2019
Q4 | $29K | Buy |
198,732
+129,287
| +186% | +$17.6K | ﹤0.01% | 6674 |
|
|
2019
Q3 | $11K | Buy |
69,445
+24,809
| +56% | +$4.48K | ﹤0.01% | 7142 |
|
|
2019
Q2 | $7K | Sell |
44,636
-32,396
| -42% | -$6.56K | ﹤0.01% | 7288 |
|
|
2019
Q1 | $15K | Buy |
77,032
+72,032
| +1,441% | +$16K | ﹤0.01% | 6569 |
|
|
2018
Q4 | $4K | Sell |
5,000
-3,688
| -42% | -$4.12K | ﹤0.01% | 7679 |
|
|
2018
Q3 | $10K | Buy |
8,688
+7,688
| +769% | +$8.6K | ﹤0.01% | 7190 |
|
|
2018
Q2 | $1K | Hold |
1,000
| – | – | ﹤0.01% | 7883 |
|
|
2018
Q1 | $2K | Sell |
1,000
-6,503
| -87% | -$12.2K | ﹤0.01% | 7586 |
|
|
2017
Q4 | $9K | Buy |
7,503
+2,660
| +55% | +$3.63K | ﹤0.01% | 7124 |
|
|
2017
Q3 | $6K | Buy |
4,843
+2,799
| +137% | +$3.58K | ﹤0.01% | 7180 |
|
|
2017
Q2 | $2K | Sell |
2,044
-6,411
| -76% | -$9.27K | ﹤0.01% | 7429 |
|
|
2017
Q1 | $15K | Buy |
8,455
+2,389
| +39% | +$10.8K | ﹤0.01% | 6366 |
|
|
2016
Q4 | $31K | Buy |
6,066
+1,340
| +28% | +$7.05K | ﹤0.01% | 6220 |
|
|
2016
Q3 | $27K | Buy |
4,726
+2,976
| +170% | +$17K | ﹤0.01% | 6049 |
|
|
2016
Q2 | $10K | Hold |
1,750
| – | – | ﹤0.01% | 6810 |
|
|
2016
Q1 | $8K | Sell |
1,750
-1,963
| -53% | -$8.08K | ﹤0.01% | 6810 |
|
|
2015
Q4 | $23K | Buy |
3,713
+763
| +26% | +$5.18K | ﹤0.01% | 6618 |
|
|
2015
Q3 | $23K | Hold |
2,950
| – | – | ﹤0.01% | 6590 |
|
|
2015
Q2 | $18K | Sell |
2,950
-9,455
| -76% | -$73.3K | ﹤0.01% | 6995 |
|
|
2015
Q1 | $100K | Buy |
12,405
+12,205
| +6,103% | +$92.1K | ﹤0.01% | 5419 |
|
|
2014
Q4 | $1K | Buy |
+200
| New | +$988 | ﹤0.01% | 9582 |
|
UBS Group's GNMX Position: Q1 2020 in Review
UBS Group sold out of Aevi Genomic Medicine Inc (GNMX) in Q1 2020, closing a stake of 198,732 shares — an estimated $29K sold.
UBS Group first reported a position in GNMX in Q4 2014 and held it in 21 quarters. The position peaked at $100K in Q1 2015. 2 funds tracked by Wall St. Rank hold GNMX as of Q1 2020.
- UBS Group reported no remaining Aevi Genomic Medicine Inc position as of Q1 2020 after selling out during the quarter.
- UBS Group sold 198,732 Aevi Genomic Medicine Inc shares in Q1 2020, an estimated $29K.
- UBS Group first reported a position in Aevi Genomic Medicine Inc in Q4 2014 and held it in 21 quarters.
- UBS Group's Aevi Genomic Medicine Inc position peaked at $100K in Q1 2015.
- 2 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q1 2020.
Based on UBS Group's 13F filing for Q1 2020, filed 1 May 2020.